best glp-1 agonist companies The Biggest Winner of with a New Drug Breakthrough GLP-1 Agonists: Using Semaglutide, Tirzepatide,

The New England Journal of Medicine, 388(11), 961963

Owing to its potential benefits in treating diabetes and off-label use for obese conditions, the molecule will bring cumulative sales of more than USD 100 billion by 2029

Despite the lack of research on tirzepatide, especially in HF patients, its cardiovascular effects indicate potential benefits for this population

In other words, we achieved a number needed to harm (NNH) as high as 1537 patients

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a type of medication originally developed to treat type 2 diabetes, but are now being used for the treatment of obesity because they are effective at helping people to lose weight

DOI: 10.1016/j.chc.2019.05.004